Abstract
w c v t i e s -Aminocaproic acid (EACA) is used to treat bleeding associated with systemic brinolysis, as well as hematuria resulting rom urinary tract procedures or tumors. EACA nhibits urokinase and other activators of plasinogen, decreasing the formation of plasmin nd inhibiting the breakdown of fibrin. ACA-associated renal failure may be caused y obstruction of the upper urinary system by lood clots, hypotension with acute tubular ecrosis, renal infarction, and myoglobinuria. his is the first report of EACA causing renal ailure by accelerating a preexisting thromotic microangiopathic process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
